Moreover, the SCCa levels of the serum samples were within the linear range of the LSPR sensor. the silver nanoparticles for distinct detection of SCCa. Different concentrations of SCCa were successfully tested in both buffer and human serum by the ultrasensitive and specific LSPR system, with a linear quantitative detection range of 0.1C1,000 pM under optimal conditions. With appropriate regeneration solution, for example 50 mM glycine-HCl (pH 2.0), the LSPR biosensor featured effective fabrication reproducibility, which reduced both production cost and testing time. Our study represents the first application of the LSPR biosensor in cervical cancer, and demonstrates that the rapid, simple, and reusable nanochip can serve as a potential alternative for clinical serological diagnosis of SCCa in cervical cancer patients. SD LW-1 antibody (n=3, nm) SD (n=3, nm)is mean of test results; =?(max)post?/(max)pre??100 SD (n3, %)is the average value of residual activity; SD (n=5, nm)is the mean of LSPR shifts obtained from initial detection and following regeneration procedures; SD (n=10, nm) SD (n=10, pM)is the mean of test results. Abbreviations: LSPR, localized surface plasmon resonance; SCCa, squamous cell carcinoma antigen; SD, standard deviation; max, peak wavelength shift/variation of LSPR spectrum. Red shifts less than 4.88 nm were observed in the controls, validating that the biosensor had good specificity and the results were reliable without disruption of other components in the serum. Moreover, the SCCa levels of the serum samples were within the linear range of the LSPR sensor. However, the sensitivity of SCCa using the LSPR system compared to pathological diagnosis was only 50% due to the limited number of subjects, indicating the necessity of large sample-size clinical research. Aside from these data, the LSPR sensor test needs to be validated by traditional methods (eg, ELISA). Also, the precision of quantitative analysis needs improvement with larger shifts from the same amount of analyte. Conclusion To the best of our knowledge, this is the first use of the LSPR method for medical diagnosis in cervical cancer patients. The experiments described in this study demonstrate O-Phospho-L-serine that: 1) a self-assembled MUA monolayer is suitable linkage for the effective immobilization of anti-SCCa onto the silver nano-chips via amino coupling; 2) the functionalized LSPR sensor is simple to prepare, can provide good sensitivity, has a low detection limit, and has good selectivity for assaying SCCa; 3) using an appropriate regeneration solution, the sensor can be reused with good signal retention, which is both time and cost efficient; 4) the custom-built LSPR system is available for quantitative analysis of SCCa level in human O-Phospho-L-serine serum with advantages in terms of a rapid test time, label-free, and dilution-free process. Further studies need to be performed to evaluate the applicability of this biosensor in medical diagnosis for gynecological malignancies with a large, blinded diagnostic trial compared to the gold standard method. Signal amplification systems should be explored in order to lower the magnitude of the detecting sensitivity, as well as improving the quantitative measurement accuracy.13 In conclusion, the LSPR biosensor is a promising platform for cancer biomarker studies and commercial application. Acknowledgments This project was financially supported by National Key Basic Research Program of China (2011CB301800) and Sichuan O-Phospho-L-serine Provincial Science and Technology Support Project (2012SZ0021). The authors thank Qianqian Gao and Lin Li for their kind contribution to this work. Footnotes Disclosure The authors report no conflicts of interest in this work..